|
|
|
|
pmid:
|
Breuer O |
Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. |
1995 |
J. Lipid Res. |
pmid:8656065
|
Breuer O et al. |
The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. |
1996 |
Biochim. Biophys. Acta |
pmid:8695664
|
Bodin K et al. |
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. |
2001 |
J. Biol. Chem. |
pmid:11514559
|
Bodin K et al. |
Metabolism of 4 beta -hydroxycholesterol in humans. |
2002 |
J. Biol. Chem. |
pmid:12077124
|
Rontani JF and Aubert C |
Electron ionization mass spectral fragmentation of cholestane-3beta,4alpha,5alpha-triol and cholestane-3beta,5alpha,6alpha/beta-triol bis- and tris-trimethylsilyl derivatives. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15954177
|
Niemi M et al. |
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. |
2006 |
Pharmacogenet. Genomics |
pmid:16847425
|
Diczfalusy U et al. |
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. |
2008 |
Pharmacogenet. Genomics |
pmid:18300941
|
Wide K et al. |
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. |
2008 |
Br J Clin Pharmacol |
pmid:18279471
|
Josephson F et al. |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. |
2008 |
Eur. J. Clin. Pharmacol. |
pmid:18458892
|
Kanebratt KP et al. |
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. |
2008 |
Clin. Pharmacol. Ther. |
pmid:18650803
|
Lütjohann D et al. |
4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. |
2009 |
Int J Clin Pharmacol Ther |
pmid:19954708
|
Tomalik-Scharte D et al. |
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? |
2009 |
Clin. Pharmacol. Ther. |
pmid:19458613
|
Honda A et al. |
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. |
2009 |
J. Lipid Res. |
pmid:18815436
|
Allmyr M et al. |
Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. |
2009 |
Basic Clin. Pharmacol. Toxicol. |
pmid:19686543
|
Diczfalusy U et al. |
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. |
2009 |
Br J Clin Pharmacol |
pmid:19006545
|
Yang Z and Rodrigues AD |
Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? |
2010 |
J Clin Pharmacol |
pmid:20197489
|
Goodenough AK et al. |
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. |
2011 |
Chem. Res. Toxicol. |
pmid:21728364
|
Peters J et al. |
Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. |
2011 |
Drug Metab. Dispos. |
pmid:21690264
|
Nylén H et al. |
Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. |
2011 |
Eur. J. Clin. Pharmacol. |
pmid:21246351
|
van de Merbel NC et al. |
A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. |
2011 |
J Pharm Biomed Anal |
pmid:21507593
|
Gebeyehu E et al. |
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. |
2011 |
Pharmacogenomics J. |
pmid:20231858
|
Diczfalusy U et al. |
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. |
2011 |
Br J Clin Pharmacol |
pmid:21219398
|
Higashi T et al. |
LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. |
2013 |
Chem. Pharm. Bull. |
pmid:23449202
|
Suzuki Y et al. |
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. |
2013 |
J. Lipid Res. |
pmid:23833241
|
Nury T et al. |
Biological activities of the LXRα and β agonist, 4β-hydroxycholesterol, and of its isomer, 4α-hydroxycholesterol, on oligodendrocytes: effects on cell growth and viability, oxidative and inflammatory status. |
2013 |
Biochimie |
pmid:23220593
|
Björkhem-Bergman L et al. |
Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. |
2013 |
Drug Metab. Dispos. |
pmid:23386704
|
Shin KH et al. |
Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. |
2013 |
Clin. Pharmacol. Ther. |
pmid:23784264
|
van de Merbel NC and de Vries R |
Aging of biological matrices and its effect on bioanalytical method performance. |
2013 |
Bioanalysis |
pmid:24066624
|
DeGorter MK et al. |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. |
2013 |
Circ Cardiovasc Genet |
pmid:23876492
|
Xu Y et al. |
LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. |
2013 |
J Pharm Biomed Anal |
pmid:23948760
|
Björkhem-Bergman L et al. |
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. |
2013 |
Drug Metab. Dispos. |
pmid:23674608
|
Mårde Arrhén Y et al. |
A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. |
2013 |
Br J Clin Pharmacol |
pmid:23116409
|
Suzuki Y et al. |
Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. |
2014 |
Drug Metab. Dispos. |
pmid:24135442
|
Dutreix C et al. |
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. |
2014 |
Eur. J. Clin. Pharmacol. |
pmid:24839948
|
Kasichayanula S et al. |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. |
2014 |
Br J Clin Pharmacol |
pmid:24837659
|
Nylén H et al. |
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. |
2014 |
Basic Clin. Pharmacol. Toxicol. |
pmid:24655660
|
Li K et al. |
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. |
2014 |
Drug Metab. Dispos. |
pmid:24595680
|
Ngaimisi E et al. |
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. |
2014 |
J. Antimicrob. Chemother. |
pmid:25096076
|
Huang MQ et al. |
Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. |
2014 |
Biomed. Chromatogr. |
pmid:24861746
|
Ikegami T et al. |
Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. |
2014 |
Biochem. Biophys. Res. Commun. |
pmid:24525121
|
Hukkanen J et al. |
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. |
2015 |
Br J Clin Pharmacol |
pmid:26095142
|
de Graan AJ et al. |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. |
2015 |
Br J Clin Pharmacol |
pmid:26119961
|
Mannheimer B et al. |
No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. |
2015 |
PLoS ONE |
pmid:25835492
|
Naito T et al. |
CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. |
2015 |
Drug Metab. Pharmacokinet. |
pmid:26654672
|
Hasan M et al. |
Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27565568
|
Vanhove T et al. |
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
2016 |
Br J Clin Pharmacol |
pmid:27501475
|
Aubry AF et al. |
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. |
2016 |
AAPS J |
pmid:27350147
|
Ishida T et al. |
Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. |
2016 |
Drug Metab. Pharmacokinet. |
pmid:27236640
|
Xue YJ et al. |
Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. |
2016 |
Bioanalysis |
pmid:26805594
|